What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.
BrainStorm Prices New Dilutive Offering; Shares Drop
Aug 14, 2013
Israel-based and perennially under-capitalized BrainStorm Cell Therapeutics
(BCLI), in its 8th year of operation under a 'going concern' warning, priced
a highly dilutive new share offer yesterday, triggering a sell-off that drove BCLI shares down 18% to $0.17
BrainStorm Receives Orphan Drug Status in EU
Jul 29, 2013
BrainStorm Cell Therapeutics announced
it has received an orphan drug designation for its NurOwn cells in the treatment of ALS from the EU. The designation could provide BrainStorm with 10 years of market exclusivity, as well as possible eligibility for certain EU grants. BCLI shares were up 17% by mid-day on the news.
BrainStorm Cell Therapeutics (BCLI) Warning
Mar 15, 2013
< Previous Page
In its FY12 annual report
, filed yesterday with the SEC, BrainStorm Cell Therapeutics
) revealed it has received a 'going concern' warning from its independent accounting firm, Deloitte. This marks at least the 8th consecutive year BrainStorm has operated under a going concern warning.
| Next Page >